These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 33357766)

  • 21. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
    Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
    J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genome editing comes of age.
    Kim JS
    Nat Protoc; 2016 Sep; 11(9):1573-8. PubMed ID: 27490630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.
    Mout R; Ray M; Lee YW; Scaletti F; Rotello VM
    Bioconjug Chem; 2017 Apr; 28(4):880-884. PubMed ID: 28263568
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ocular delivery of CRISPR/Cas genome editing components for treatment of eye diseases.
    Yu W; Wu Z
    Adv Drug Deliv Rev; 2021 Jan; 168():181-195. PubMed ID: 32603815
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genome Editing: A New Horizon for Oral and Craniofacial Research.
    Yu N; Yang J; Mishina Y; Giannobile WV
    J Dent Res; 2019 Jan; 98(1):36-45. PubMed ID: 30354846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [CRISPR/Cas9 technology in disease research and therapy: a review].
    Shi M; Shen Z; Zhang N; Wang L; Yu C; Yang Z
    Sheng Wu Gong Cheng Xue Bao; 2021 Apr; 37(4):1205-1228. PubMed ID: 33973436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A beginner's guide to gene editing.
    Harrison PT; Hart S
    Exp Physiol; 2018 Apr; 103(4):439-448. PubMed ID: 29282799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent advances in genome editing of stem cells for drug discovery and therapeutic application.
    Lee J; Bayarsaikhan D; Bayarsaikhan G; Kim JS; Schwarzbach E; Lee B
    Pharmacol Ther; 2020 May; 209():107501. PubMed ID: 32061705
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retroviral Vectors for Cancer Gene Therapy.
    Schambach A; Morgan M
    Recent Results Cancer Res; 2016; 209():17-35. PubMed ID: 28101685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-Viral Delivery To Enable Genome Editing.
    Rui Y; Wilson DR; Green JJ
    Trends Biotechnol; 2019 Mar; 37(3):281-293. PubMed ID: 30278987
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease.
    Doetschman T; Georgieva T
    Circ Res; 2017 Mar; 120(5):876-894. PubMed ID: 28254804
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Highly Efficacious PS Gene Editing System Corrects Metabolic and Neurological Complications of Mucopolysaccharidosis Type I.
    Ou L; Przybilla MJ; Ahlat O; Kim S; Overn P; Jarnes J; O'Sullivan MG; Whitley CB
    Mol Ther; 2020 Jun; 28(6):1442-1454. PubMed ID: 32278382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Delivery technologies for genome editing.
    Yin H; Kauffman KJ; Anderson DG
    Nat Rev Drug Discov; 2017 Jun; 16(6):387-399. PubMed ID: 28337020
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel vectors and approaches for gene therapy in liver diseases.
    Maestro S; Weber ND; Zabaleta N; Aldabe R; Gonzalez-Aseguinolaza G
    JHEP Rep; 2021 Aug; 3(4):100300. PubMed ID: 34159305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genome editing and kidney health.
    Tavakolidakhrabadi N; Aulicino F; May CJ; Saleem MA; Berger I; Welsh GI
    Clin Kidney J; 2024 May; 17(5):sfae119. PubMed ID: 38766272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of the gene editing tool, CRISPR-Cas9, for treating neurodegenerative diseases.
    Kolli N; Lu M; Maiti P; Rossignol J; Dunbar GL
    Neurochem Int; 2018 Jan; 112():187-196. PubMed ID: 28732771
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic and diagnostic relevance of Crispr technology.
    El Ouar I; Djekoun A
    Biomed Pharmacother; 2021 Jun; 138():111487. PubMed ID: 33774312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Research on genodermatoses using novel genome-editing tools.
    Lehmann J; Seebode C; Emmert S
    J Dtsch Dermatol Ges; 2017 Aug; 15(8):783-789. PubMed ID: 28622433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A primer to gene therapy: Progress, prospects, and problems.
    Zittersteijn HA; Gonçalves MAFV; Hoeben RC
    J Inherit Metab Dis; 2021 Jan; 44(1):54-71. PubMed ID: 32510617
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Footprint-free gene mutation correction in induced pluripotent stem cell (iPSC) derived from recessive dystrophic epidermolysis bullosa (RDEB) using the CRISPR/Cas9 and piggyBac transposon system.
    Itoh M; Kawagoe S; Tamai K; Nakagawa H; Asahina A; Okano HJ
    J Dermatol Sci; 2020 Jun; 98(3):163-172. PubMed ID: 32376152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.